Retinoic acid (RA), the active metabolite of vitamin A, is a crucial signaling molecule in neural development, synaptic plasticity, and neuronal survival. Retinoic acid signaling dysregulation contributes to multiple neurodegenerative diseases, making it a potential therapeutic target [@treatment]. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
¶ Overview and Biological Significance
Retinoic acid serves as a critical morphogen during central nervous system development, regulating neuronal differentiation, axon guidance, and pattern formation [@mark1998]. Beyond development, RA continues to play essential roles in the adult brain, including synaptic plasticity, hippocampal-dependent learning, and neurogenesis [@kane2000]. The nuclear receptors for RA—retinoic acid receptors (RARs) and retinoid X receptors (RXRs)—are widely expressed throughout the brain, enabling RA to modulate diverse cellular processes.
The significance of RA signaling in neurodegeneration stems from several key observations: (1) RA levels decline with aging in the brain; (2) RA target genes are downregulated in Alzheimer's disease and Parkinson's disease brains; (3) RA receptor expression is altered in neurodegenerative conditions; and (4) retinoid-based interventions show neuroprotective effects in multiple models [@bonnefont2011].
Retinoic acid is synthesized through a tightly regulated two-step enzymatic process:
-
Retinol (vitamin A) → Retinaldehyde (retinal): This oxidation is catalyzed by alcohol dehydrogenases (ADH) and retinol dehydrogenases (RDH). The retinaldehyde intermediate can also be generated from β-carotene via cleavage with β-carotene oxygenase (BCO1).
-
Retinaldehyde → Retinoic acid: This irreversible oxidation is catalyzed by retinaldehyde dehydrogenases (RALDH1-3, also known as ALDH1A1-3). RALDH1 is expressed in the hippocampus, RALDH2 is prominent during development, and RALDH3 is found in specific brain regions [@corcoran2004].
flowchart TD
A["Dietary Vitamin A<br/>Retinol"] --> B["Alcohol Dehydrogenases<br/>ADH/RDH"]
B --> C["Retinaldehyde<br/>(Retinal)"]
C --> D["Retinaldehyde Dehydrogenases<br/>RALDH1-3"]
D --> E["Retinoic Acid<br/>(Active Metabolite)"]
E --> F["Nuclear Receptor Binding"]
F --> G["RAR α/β/γ"]
F --> H["RXR α/β/γ"]
G --> I["Gene Transcription<br/>Activation"]
H --> I
I --> J["Neuronal Differentiation"]
I --> K["Synaptic Plasticity"]
I --> L["Neuroprotection"]
I --> M["Adult Neurogenesis"]
¶ RA Transport and Storage
RA is a lipophilic molecule requiring specific transport mechanisms:
- Cellular retinol-binding protein (CRBP): Facilitates intracellular retinol transport
- Cellular retinoic acid-binding protein (CRABP): Controls RA availability and degradation
- Albumin: Major carrier in blood circulation
- Synaptic vesicle packaging: RA can be packaged and released from synaptic terminals
The RAR family consists of three subtypes (α, β, γ), each with multiple isoforms generated through alternative promoter usage and splicing [@lane2010]:
| Receptor |
Isoforms |
Brain Expression |
Key Functions |
| RARα |
α1, α2 |
Ubiquitous |
Development, apoptosis regulation |
| RARβ |
β1-β4 |
Brain-enriched |
Neuronal differentiation, survival |
| RARγ |
γ1, γ2 |
Developing brain |
Patterning, cell fate determination |
RXRs function as heterodimerization partners with RARs and other nuclear receptors:
| Receptor |
Expression |
Function |
| RXRα |
Ubiquitous |
Master regulator, partner for RARs, PPARs, LXRs |
| RXRβ |
Brain-enriched |
Neural development, behavior |
| RXRγ |
Specific regions |
Motor function, synaptic plasticity |
RA signaling occurs through multiple mechanisms:
-
Genomic (transcriptional): RA-RAR-RXR complexes bind to retinoic acid response elements (RAREs) in target gene promoters, recruiting coactivators or corepressors to regulate transcription.
-
Non-genomic (rapid): RA can activate signaling pathways independently of transcriptional effects, including MAPK/ERK, PI3K/Akt, and PKC pathways [@gronemeyer2004].
flowchart LR
A["Retinoic Acid<br/>Ligand"] --> B["RAR/RXR<br/>Heterodimer"]
B --> C["RARE Binding<br/>Gene Promoter"]
C --> D["Coactivator<br/>Recruitment"]
D --> E["Target Gene<br/>Transcription"]
B --> F["Rapid Signaling<br/>Non-Genomic"]
F --> G["MAPK/AKT/PKC<br/>Pathways"]
E --> H["Differentiation"]
E --> I["Survival"]
E --> J["Plasticity"]
F --> K["Acute Effects<br/>on Signaling"]
Retinoic acid signaling is profoundly altered in AD, contributing to multiple aspects of disease pathogenesis [@bonnefont2011]:
Amyloid Processing and Metabolism:
- RARα activation promotes α-secretase activity, shifting APP processing away from amyloidogenic β/γ-secretase pathways
- RA reduces Aβ production in cellular models
- Retinoids enhance expression of ADAM10 (α-secretase)
Tau Phosphorylation:
- RA modulates tau kinases (GSK3β, CDK5) and phosphatases (PP2A)
- RA deficiency may contribute to tau hyperphosphorylation
- Retinoid treatment reduces tau pathology in models
Synaptic Function and Neurogenesis:
- RA regulates synaptophysin and other synaptic protein expression
- Adult hippocampal neurogenesis is enhanced by RA signaling
- RA deficiency in the aging brain may contribute to cognitive decline
Neuroinflammation:
- RA modulates microglial activation and cytokine production
- Anti-inflammatory effects of RA may be protective in AD
RA signaling is implicated in PD through several mechanisms [@mcilroy2016]:
Dopaminergic Neuron Protection:
- RA protects SH-SY5Y cells and primary neurons from 6-OHDA toxicity
- RA upregulates neurotrophic factors (BDNF, GDNF)
- RARβ expression is reduced in PD substantia nigra
Alpha-Synuclein Regulation:
- RA regulates SNCA gene expression [@jiang2018]
- RXRγ deficiency accelerates α-synuclein pathology [@goncalves2019]
- Retinoids may reduce α-synuclein aggregation
Dopamine Signaling:
- RA modulates dopamine receptor expression
- Influences levodopa response and dyskinesia development
Retinoid signaling alterations in ALS include [@mhare2021]:
- Motor Neuron Development: RARβ is crucial for motor neuron survival
- Glutamate Excitotoxicity: RA modulates glutamate transporter expression (EAAT2)
- SOD1 Models: Altered RA signaling in SOD1 transgenic mice
- Inflammation: RA modulates neuroinflammation in ALS models
RA signaling in HD:
- BDNF Expression: RA regulates BDNF expression (protective in HD)
- Neural Progenitors: RA enhances differentiation of neural stem cells
- Motor Function: Vitamin A supplementation shows promise in models
| Compound |
Target |
Stage |
Notes |
| All-trans retinoic acid (ATRA) |
RARs |
Clinical trials |
Approved for APL, exploring AD/PD |
| 9-cis Retinoic acid |
RAR/RXR |
Preclinical |
Pan-agonist, discontinued |
| Selective RARβ agonists |
RARβ |
Research |
Brain-specific, promising |
| RAR antagonists |
RARα |
Research |
May reduce toxicity |
| Bexarotene |
RXR selective |
Preclinical |
Repurposed for neurodegeneration |
Several clinical investigations have explored retinoid-based approaches:
- ATRA in AD: Phase II completed (NCT01714010), showing safety and some cognitive benefits
- Bexarotene in AD: Pilot study showed reduction in Aβ plaques
- Vitamin A/C supplementation in MCI: Ongoing studies
- Retinoid derivatives for PD: Preclinical validation continues
¶ Challenges and Limitations
The translation of retinoid-based therapies has faced significant challenges:
| Challenge |
Description |
Mitigation Strategies |
| Toxicity |
High doses cause teratogenicity, hypervitaminosis A |
Lower doses, selective agonists |
| Blood-brain barrier |
Limited penetration of retinoids |
Novel formulations, prodrugs |
| Isoform specificity |
Pan-RAR activation causes side effects |
Selective RARβ agonists |
| Variable response |
Patient genetic variability affects response |
Pharmacogenomics approaches |
¶ Molecular Pathways and Interactions
flowchart TD
A["RA Treatment"] --> B["RAR/RXR Activation"]
B --> C["Anti-apoptotic Signaling"]
B --> D["Antioxidant Response"]
B --> E["Autophagy Activation"]
B --> F["Neurotrophic Factor Expression"]
C --> G["Bcl-2 Upregulation"]
C --> H["Caspase Inhibition"]
D --> I["Nrf2 Activation"]
D --> J["ROS Scavenging"]
E --> K["mTOR Inhibition"]
E --> L["Autophagosome Formation"]
F --> M["BDNF Expression"]
F --> N["GDNF Expression"]
G --> O["Neuronal Survival"]
H --> O
I --> O
J --> O
K --> O
L --> O
M --> O
N --> O
RA signaling intersects with multiple key pathways in neurodegeneration:
- Wnt/β-catenin: RA and Wnt pathways synergize in neural development
- Notch: RA modulates Notch signaling during neurogenesis
- BDNF/Neurotrophin: RA enhances BDNF expression and signaling
- NF-κB: RA has anti-inflammatory effects via NF-κB modulation
- Brain-penetrant retinoids: Developing compounds that crosses the BBB efficiently
- Selective RARβ agonists: Targeting specific receptor subtypes for neuroprotection
- RXR modulators: Exploiting RXR's role in neuronal survival
- Gene therapy: AAV-mediated RARβ expression in the brain
- RA with cholinesterase inhibitors for AD
- RA with neurotrophic factors
- RA with antioxidants
- RA with anti-inflammatory agents
- Retinoic acid response genes as pharmacodynamic markers
- RA metabolite levels as disease biomarkers
- RAR/RXR expression as patient selection criteria
Retinoic acid signaling represents a fundamental pathway in neuronal function and survival, with clear implications for neurodegenerative disease pathogenesis and therapy. The pleiotropic effects of RA on amyloid processing, tau phosphorylation, synaptic plasticity, neurogenesis, and neuroinflammation make it an attractive therapeutic target. However, significant challenges remain in translating basic science findings into effective treatments, particularly regarding toxicity and brain penetration. Future directions include developing brain-penetrant selective retinoid receptor agonists, exploiting combination strategies, and identifying biomarkers to enable personalized treatment approaches.
- Mark M, et al., Retinoic acid and neuronal differentiation (1998)
- Kane MA, et al., Retinoid signaling in the adult brain (2000)
- Bonnefont J, et al., Retinoic acid as a candidate for Alzheimer's disease therapy (2011)
- Corcoran J, et al., Retinoid signaling and neurogenesis in adult neural stem cells (2004)
- Lane MA, et al., Retinoids and their receptors in the central nervous system (2010)
- McIlroy G, et al., Retinoic acid and Parkinson's disease (2016)
- Goncalves L, et al., Retinoid X receptor gamma deficiency accelerates Parkinson's disease (2019)
- Jiang H, et al., Retinoic acid regulates alpha-synuclein expression (2018)
- Mhare T, et al., Retinoid signaling in ALS (2021)
- Conte M, et al., Retinoic acid in nervous system development and regeneration (2010)
- Gronemeyer H, et al., The nuclear receptor function and gene regulation (2004)
- Extracellular vesicles in Parkinson's disease model (2026)
- KCL-286 treatment for spinal cord injury (2026)
- Multi-kinase-mediated alterations in Tau phosphorylation (2026)
- TIM-3 expression in microglia during AD progression (2026)
- Dopamine receptor changes influence tau pathology (2025)